Objective To investigate the value of transient elastography ( TE) in the diagnosis of nonalcoholic fatty liver disease ( NAFLD) . Methods A total of 21 patients without fatty liver disease and 92 patients with NAFLD, who visited Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region from June to December, 2016, were enrolled. Their general information was collected and body mass index ( BMI) was calculated. Routine blood test, liver function evaluation, and measurement of blood lipid, serum insulin, and alpha-fetoprotein were performed, and liver CT and Fibro Touch were performed. The receiver operating characteristic ( ROC) curve was plotted with liver/spleen CT ratio as diagnostic criteria, and the ROC curve was used to evaluate the ability of controlled attenuation parameter ( CAP) to diagnose NAFLD. The area under the ROC curve ( AUC) was calculated, the Z test was used to evaluate diagnostic effectiveness, and Youden index was used to determine the optimal cut-off value. The t-test was used for comparison of normally distributed continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between any two groups. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups. The chi-square test was used for comparison of categorical data between groups. Results There were significant differences in age, alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , serum insulin, fat attenuation, and liver stiffness measurement ( LSM) between the patients without fatty liver disease and those with varying degrees of NAFLD ( all P < 0. 05) . The severe NAFLD group had a significantly lower mean age than the non-fatty liver disease group ( P < 0. 001) . There was a significant difference in CAP between the non-fatty liver disease group and the groups with varying degrees of NAFLD ( all P < 0. 001) , while there was no significant difference in CAP between the moderate and severe NAFLD groups ( P = 0. 127) . There was a significant difference in LSM between the non-fatty liver disease group and the moderate NAFLD group ( P = 0. 034) , as well as between the non-fatty liver disease group and the severe NAFLD group ( P < 0. 001) , while there was no significant difference between the moderate and severe NAFLD groups ( P = 0. 327) . There were significant differences in the levels of ALT and AST between the non-fatty liver disease group and the groups with varying degrees of NAFLD ( all P < 0. 001) , and the severe NAFLD group had significantly higher levels of ALT and AST than the mild NAFLD group ( both P =0. 001) . There was a significant difference in the level of insulin between the non-fatty liver disease group and the groups with varying degrees of NAFLD, while there was no significant difference between the groups with varying degrees of NAFLD ( all P > 0. 05) . The optimal cut-off values of CAP for the diagnosis of mild, moderate, and severe NAFLD were 244 d B/m, 272 d B/m, and 272 d B/m, respectively, with AUC of 0. 778 ( 95% confidence interval [CI]: 0. 663-0. 894) , 0. 893 ( 95% CI: 0. 809-0. 976) , and 0. 942 ( 95% CI: 0. 886-0. 998) ( all P < 0. 001) . Conclusion TE is a reliable noninvasiveness method for the diagnosis of NAFLD. CAP can accurately and quantitatively evaluate the degree of NAFLD and effectively differentiate mild NAFLD from moderate or severe NAFLD and thus has a good value in the grading of NAFLD. But it is difficult to differentiate moderate NAFLD from severe NAFLD.
[1]LEWIS JR, COHANTY SR.Nonalcoholic fatty liver diease:a review and update[J].Dig Dis Sci, 2010, 55 (3) :560-578.
|
[2]CHANG BX, LI BS, ZOU ZS.An except of EASL-EASD-EASOclinical practice guidelines for the management of non-alcoholic fatty liver disease (2016) [J].J Clin Hepatol, 2016, 32 (8) :1450-1454. (in Chinese) 常彬霞, 李保森, 邹正升.《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南:非酒精性脂肪性肝病》摘译[J].临床肝胆病杂志, 2016, 32 (8) :1450-1454.
|
[3]ZHU JZ, DAI YN, WANG YM, et al.Prevalence of nonalcoholic fatty liver disease and economy[J].Dig Dis Sci, 2015, 60 (11) :3194-3202.
|
[4]FAN JG, FARRBLL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol, 2009, 50 (1) :204-210.
|
[5]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.
|
[6]WU XM.Detection of fatty liver disease in people undergoing physical examination and related factors:an analysis of 867 cases[J].Jilin Med J, 2012, 33 (6) :1154-1155. (in Chinese) 吴晓铭.867例健康体检中脂肪肝检验结果与相关因素分析[J].吉林医学, 2012, 33 (6) :1154-1155.
|
[7] SCHWENZER NF, SPRINGER F, SCHRAML C, et al.Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance[J].J Hepatol, 2009, 51 (3) :433-445.
|
[8]LEE SS, PARK SH, KIM HJ, et al.Non-invasive assessment of hepatic steatosis:prospective comparion of the accuracy of imaging examinations[J].J Hepatol, 2010, 52:579-585.
|
[9]LONGO R, RICCI C, MASUTTI F, et al.Fatty infiltration of the liver.Quantification by IH localized magnetic resonance spectroscopy and comparison with computed tomography[J].Invest Radiol, 1993, 28:297-302.
|
[10]BANERJEE R, PAVLIDES M, TUNLIFFE EM, et al.Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease[J].J Hepatol, 2014, 60:69-77.
|
[11]SCHWENZER NE, SPRINGER F, SCHRAML C, et al.Non-invasive assessment and quantificaton of liver steatosis by ultrasound, computed tomography and magnetic resonance[J].J Hepatol, 2009, 51 (3) :433-445.
|
[12]HOU FF, QI XS.Elastography assessment of liver fibrosis:society of radiologisis in ultrasound conference statement[J].J Clin Hepatol, 2015, 31 (9) :1384-1388. (in Chinese) 侯飞飞, 祁兴顺.《2015年美国超声放射医师学会共识声明:弹性成像评估肝纤维化》摘译[J].临床肝胆病杂志, 2015, 31 (9) :1384-1388.
|
[13]SASSO M, BEAUGAND M, DE LEDINGHEN V, et al.Controlled attenuation parameter (CAP) :a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis:preliminary study and validation in a cohort of patients with chronic liver disease from various causes[J].Ultrasound Med Biol, 2010, 36 (11) :1825-1835.
|
[14]SHEN F, ZHENG RD, MI YQ, et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol, 2014, 20 (16) :4702-4711.
|
[15]BYENE CD, TARGHER G.NAFLD:a multisystem disease[J].JHepatol, 2015, 62 (1 Suppl) :s47-s64.
|
[16]RINELLA ME.Nonalcohholic fatty liver disease:a systmatic review[J].JAMA, 2015, 313 (22) :2263-2273.
|
[17]MI YQ, SHI QY, XU L, et al.CAP for noninvasive assessment of hepatic steatosis using Fibroscan:validation in chronic hepatiis B[J].Dig Dis Sci, 2015, 60 (1) :243-251.
|
[18]SHEN F, ZHWENG RD, SHI JP, et al.Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J].Liver Int, 2015, 35 (11) :2392-2400
|
[19]LI JB, LIU S, WEN B, et al.Clinical significance of Fibro Touch, ultrasound, and computed tomography in diagnosis of fatty liver disease:a comparative analysis[J].J Clin Hepatol, 2016, 32 (3) :459-462. (in Chinese) 李静波, 刘姝, 温博, 等.Fibro Touch与B超、CT对脂肪肝的诊断价值比较[J].临床肝胆病杂志, 2016, 32 (3) :459-462.
|